SABCS 2020: Does Breast Cancer Influence Mortality From COVID-19?
Posted: Thursday, December 10, 2020
There appeared to be a greater risk of unfavorable outcomes in patients with cancer infected with SARS-CoV-2. Ali Raza Khaki, MD, of Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, and colleagues determined there was a detrimental impact of COVID-19 in patients with active or a history of breast cancer. The researchers analyzed data from the CCC19 study and presented their findings at the 2020 San Antonio Breast Cancer Symposium (SABCS; Abstract PS7-01).
“This represents the largest study to date of COVID-19 outcomes in patients with invasive breast cancer,” the study authors concluded. “Nearly half of the patients with breast cancer required hospitalization during their COVID-19 disease course, and we observed a 9% 30-day all-cause mortality.”
Data from 529 patients with invasive breast cancer and COVID-19 were accrued from the CCC19 study. The de-identified data obtained included cancer history, patient demographics, outcomes of COVID-19, and clinical course.
A total of 98% of patients were women, and 70% were aged 60 or older. Ethnicities of the patients included non-Hispanic White (52%), non-Hispanic Black (22%), Hispanic (13%), and other races (11%). Of the participants, 34% had a history of smoking, 14% had an
Eastern Cooperative Oncology Group performance status of 2 or greater, 36% had more than two active diseases, 12% had stage IV disease, and 50% were undergoing cancer treatment within 3 months of a COVID-19 diagnosis. A total of 47% of patients were hospitalized, and the 30-day all-cause mortality was 9%. Of the deaths, 10% of patients were on cytotoxic systemic therapy, 5% were on noncytotoxic systemic therapy, and 12% were on local therapy.
Disclosure: For full disclosures of the study authors, visit sabcs.org.